Abstract: Provided is a liquid crystal handwriting board. The liquid crystal handwriting board includes: a liquid crystal panel, a photosensitive assembly, and a control assembly; wherein the liquid crystal panel includes a first substrate and a second substrate that are opposite; the photosensitive assembly includes a plurality of photosensitive elements; and the control assembly is electrically connected to the liquid crystal panel and the photosensitive assembly, and is configured to determine position information of a pixel region for erasure by detecting position information of target light irradiated to the liquid crystal panel by the photosensitive assembly and supply a pixel voltage to the plurality of pixel electrodes in the pixel region for erasure, such that a voltage difference is present between the plurality of pixel electrodes in the pixel region for erasure and the common electrode.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and their uses.

Abstract: A display substrate includes a display region, and the display region includes an open pore region, a first pixel region and an isolation region; the isolation region is located between the first pixel region and the open pore region, the isolation region surrounds the open pore region, and a boundary line between the open pore region and the isolation region is a cutting line; the display substrate further includes: a fracture barrier structure, a peel-off barrier structure and an encapsulation structure, the fracture barrier structure being located in an isolation region, the isolation region including a reserved cutting transition region located between the fracture barrier structure and the open pore region; a peel-off barrier structure being located in the reserved cutting transition region; the distance L between the side of the peel-off barrier structure closest to the open pore region and the cutting line being such that: 0 ?m?L?30 ?m; a first portion of the encapsulation structure being located on a

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with bortezomib and dexamethasone.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with pomalidomide and dexamethasone.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with bortezomib, melphalan and prednisone.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with lenalidomide and dexamethasone.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and their uses.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with bortezomib, melphalan and prednisone.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with bortezomib and dexamethasone.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and their uses.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with lenalidomide and dexamethasone.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with pomalidomide and dexamethasone.

Abstract: The disclosure discloses a method and apparatus for measuring a size of a crystal grain, and a method for fabricating a poly-silicon thin film. The method for measuring the size of the crystal grain includes: obtaining a grain morphology image of a crystalline region of a crystal, and drawing a grain interface diagram according to the grain morphology image; measuring at least one crystal grain in the grain interface diagram, and determining a transverse size and a longitudinal size of each measured crystal grain; and determining a transverse size and a longitudinal size of a crystal grain of the crystal according to the transverse size and the longitudinal size of each measured crystal grain.

Abstract: The disclosure discloses a method and apparatus for measuring a size of a crystal grain, and a method for fabricating a poly-silicon thin film. The method for measuring the size of the crystal grain includes: obtaining a grain morphology image of a crystalline region of a crystal, and drawing a grain interface diagram according to the grain morphology image; measuring at least one crystal grain in the grain interface diagram, and determining a transverse size and a longitudinal size of each measured crystal grain; and determining a transverse size and a longitudinal size of a crystal grain of the crystal according to the transverse size and the longitudinal size of each measured crystal grain.